Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $659,481.48 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,459 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $69.72, for a total transaction of $659,481.48. Following the completion of the transaction, the senior vice president owned 17,294 shares in the company, valued at approximately $1,205,737.68. This trade represents a 35.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total value of $27,527.55.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics stock opened at $70.88 on Thursday. The firm has a 50-day moving average of $64.29 and a 200-day moving average of $44.86. The stock has a market cap of $4.27 billion, a PE ratio of -36.54 and a beta of -0.26. Oruka Therapeutics, Inc. has a 52-week low of $10.77 and a 52-week high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. Equities research analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

ORKA has been the topic of several recent research reports. Barclays raised their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a report on Wednesday, June 3rd. Finally, Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $131.30.

Institutional Trading of Oruka Therapeutics

Several large investors have recently made changes to their positions in ORKA. Goldman Sachs Group Inc. acquired a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $2,505,000. JPMorgan Chase & Co. boosted its position in shares of Oruka Therapeutics by 567.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after acquiring an additional 13,115 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $28,000. Rhumbline Advisers acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $320,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $96,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.